# OncoHost Links 82 Plasma Proteins to TKI Sensitivity in Kidney Cancer at ESMO 2026 > OncoHost presented ESMO 2026 research linking 82 of 169 plasma proteins to angiogenesis, backing a Dana-Farber model that flags TKI benefit in kidney cancer. - Published: 2026-10-26T08:16:40+00:00 - Section: Research & Clinical Trials - Author: News Desk - URL: https://newsforagent.com/news/2026-10-26/oncohost-plasma-proteomics-tki-kidney-cancer - Source: [PR Newswire](https://www.prnewswire.com/news-releases/oncohost-presents-new-research-revealing-biological-drivers-of-tki-sensitivity-in-metastatic-renal-cell-carcinoma-at-esmo-2026-302919130.html) ## Key takeaways - OncoHost presented ESMO 2026 research on plasma proteomics and TKI sensitivity in metastatic renal cell carcinoma. - Of 169 core predictive proteins, 82 were associated with angiogenesis and vascular remodeling. - TKI-Positive patients had longer overall survival on ICI-TKI therapy versus dual immunotherapy, with a hazard ratio of 0.14 and p=0.003. OncoHost presented research at ESMO 2026 linking pretreatment plasma proteomics to tyrosine kinase inhibitor sensitivity in metastatic renal cell carcinoma, with 82 of 169 core predictive proteins associated with angiogenesis and vascular remodeling. The company said the study was presented at the European Society for Medical Oncology Congress, held October 23 to 27 in Madrid, Spain. The announcement was distributed by [PR Newswire](https://www.prnewswire.com/news-releases/oncohost-presents-new-research-revealing-biological-drivers-of-tki-sensitivity-in-metastatic-renal-cell-carcinoma-at-esmo-2026-302919130.html). ## What the ESMO Study Found The study, "Plasma Proteomics Reveals the Biological Landscape of Tyrosine Kinase Inhibitors (TKI) Sensitivity in Metastatic Renal Cell Carcinoma," was presented by Liliana Ascione as poster 3599P in the renal cancer session on October 23. The model, developed through a collaboration between [OncoHost](https://akta.pro/company-profiles/0000mtz/oncohost) and [Dana-Farber Cancer Institute](https://akta.pro/company-profiles/00004tk/dana-farber-cancer-institute), uses pretreatment plasma proteins to classify patients as TKI-Positive or TKI-Negative, indicating who is more likely to benefit from first-line ICI-TKI combination therapy versus dual immunotherapy. Wenxin Xu, MD, oncologist and principal investigator at Dana-Farber Cancer Institute, said, "We previously identified a plasma proteomic score associated with better outcomes after VEGFR TKI treatment in renal cell carcinoma (RCC)." Xu added that the new work shows vascular remodeling, angiogenesis, inflammation, and extracellular matrix remodeling pathways form the basis of TKI sensitivity in RCC. Dana-Farber named Eliezer Van Allen, MD, its inaugural chief AI officer, with a September start date, according to Beckershospitalreview. ## OncoHost's Funding and Partnerships OncoHost is a clinical-stage precision oncology company that uses AI-driven plasma proteomics to predict cancer patient response to immunotherapy, according to akta.pro [company records](https://akta.pro/company-data). Its PROphet platform analyzes over 7,000 circulating proteins to guide first-line treatment decisions for oncologists across U.S. cancer centers. The company has six funding rounds on record, including a $35 million Series C in May 2022 led by ALIVE Israel HealthTech Fund and a $2.8 million grant in May 2025 led by the European Innovation Council. Total funding stands at $55.4 million, and the company is headquartered in Binyamina, Israel. ## Other ESMO 2026 Data Genialis presented data at ESMO 2026 showing its biology-first AI models predict treatment response in small oncology cohorts, with an NSCLC model achieving an AUROC of 0.8 versus 0.6, according to [FinancialContent Business Page](https://www.financialcontent.com/article/bizwire-2026-10-23-from-small-clinical-trials-to-a-single-patient-genialis-demonstrates-the-power-of-biology-first-ai-in-cancer-research). Zentalis Pharmaceuticals reported interim overall survival data from DENALI Part 1b in platinum-resistant ovarian cancer, with a median OS of 15.8 months in Cyclin E1-positive patients on azenosertib monotherapy, according to [TradingView](https://www.tradingview.com/news/tradingview:d6aa3729f9ac2:0-zentalis-pharmaceuticals-inc-zntl-reports-interim-os-signal-in-denali-part-1b/). Precede Biosciences presented ESMO 2026 data on plasma profiling of 57 metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617, according to [FinancialContent Business Page](https://www.financialcontent.com/article/gnwcq-2026-10-23-precede-biosciences-presents-esmo-2026-data-revealing-biology-associated-with-response-and-resistance-to-psma-directed-radioligand-therapy-in-advanced-prostate-cancer). ## What Comes Next for the Model The ESMO analysis supports biological plausibility while generating hypotheses for further investigation, the company said. Ofer Sharon, MD, CEO of OncoHost, said, "What makes these findings compelling is the convergence of the mathematics, the biology, and, most importantly, the clinical signal." ## Companies in this story - [OncoHost company profile](https://akta.pro/company-profiles/0000mtz/oncohost) · website: http://oncohost.com - [Dana-Farber Cancer Institute company profile](https://akta.pro/company-profiles/00004tk/dana-farber-cancer-institute) · website: http://www.dana-farber.org --- News for Agent · https://newsforagent.com/llms.txt